EUVIMEDEUVIMED entdecken
Qualitative StudieOpen Access

An exploratory, qualitative study of treatment preferences among participants in a TB therapeutic trial

F Mugodhi, C Kanyama, F Makiya, J Metcalfe, C Potani, K K Scarsi, I Weir, J Furin, A5362/CLO-FAST study team

IJTLD Open · 2026-07 · 3 (7) · 466-470

DOI: 10.5588/ijtldopen.26.0179 ↗

Kurz gefasst

Qualitative Studie in der Zeitschrift IJTLD Open, online erschienen am 01.07.2026. Verfasst von F Mugodhi und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Zimbabwe-Clinical Trials Research Centre (UZ-CTRC), Harare, Zimbabwe. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND TB is a leading cause of morbidity and mortality, and TB treatment shortening is a focus of TB therapeutic trials. Clofazimine (CFZ) has been proposed as part of a shorter TB regimen but the drug causes skin hyperpigmentation. Patient preferences around shorter regimens with CFZ should be documented. METHODS We performed an exploratory, qualitative sub-study using in-depth interviews among purposively selected participants in the CLO-FAST trial ( NCT04311502 ). Participants were asked about their experience with their assigned treatment regimen and about preferences for treatment. Data were analysed by trained qualitative researchers using the theoretical framework of acceptability. RESULTS Twenty-three participants from India, Malawi, and Zimbabwe were selected from 89 participants randomised to two study arms in the parent trial. Most participants expressed preference for shorter regimen even if it led to skin hyperpigmentation. Preferences for a longer regimen may have been influenced by anticipated concerns around inadvertent disclosure and by a belief that longer regimens were more potent. CONCLUSION Preference assessment can be successfully built into therapeutic TB trials. Most participants preferred shorter treatment but concerns about potency and skin discolouration were expressed. Additional work is needed to describe therapeutic preferences among people with TB.

Schlagwörter

Stichwörter der Autor:innen

NCT04311502clinical trialclofaziminehyperpigmentationpreferencesstigmatuberculosis

Autor:innen und Institutionen

  • University of Zimbabwe-Clinical Trials Research Centre (UZ-CTRC), Harare, Zimbabwe.
  • University of North Carolina Project, Lilongwe, Malawi.
  • Johns Hopkins Project, Blantyre Clinical Research Site, Blantyre, Malawi.
  • Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital and Trauma Center, University of California, San Francisco (UCSF), CA, USA.
  • College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA.
  • Center for Biostatistics in AIDS Research in the Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Förderung

  • NIAID NIH HHS

Zitieren

APA

Mugodhi, F., Kanyama, C., Makiya, F., Metcalfe, J., Potani, C., Scarsi, K. K., Weir, I., Furin, J., & A5362/CLO-FAST study team (2026). An exploratory, qualitative study of treatment preferences among participants in a TB therapeutic trial. IJTLD Open, 3(7), 466-470. https://doi.org/10.5588/ijtldopen.26.0179

Vancouver

Mugodhi F, Kanyama C, Makiya F, Metcalfe J, Potani C, Scarsi KK, et al. An exploratory, qualitative study of treatment preferences among participants in a TB therapeutic trial. IJTLD Open. 2026;3(7):466-470. doi:10.5588/ijtldopen.26.0179

BibTeX
@article{Mugodhi2026,
  author = {Mugodhi, F and Kanyama, C and Makiya, F and Metcalfe, J and Potani, C and Scarsi, K K and Weir, I and Furin, J and A5362/CLO-FAST study team, A5362/CLO-FAST study team},
  title = {An exploratory, qualitative study of treatment preferences among participants in a TB therapeutic trial},
  journal = {IJTLD Open},
  year = {2026},
  volume = {3},
  number = {7},
  pages = {466--470},
  doi = {10.5588/ijtldopen.26.0179}
}
Kostenlos starten →